Adrixetinib for hard-to-treat chronic GvHD
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests an experimental drug called adrixetinib (Q702) for people with active chronic graft-versus-host disease that has not responded well to standard treatments. It aims to see if the drug can help control your symptoms when other options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate or severe chronic graft-versus-host disease that needs treatment with medicines that calm the immune system.
- Your chronic GVHD has either gotten worse after standard treatments, or your doctor thinks you need a new type of treatment.
- You had a stem cell transplant (allogeneic HSCT) at some point in the past.
- Your organs (like your liver, kidneys, and bone marrow) are working well enough, and you are able to do most daily activities (Karnofsky score of 60% or higher).
- You have not taken a CSF1R inhibitor drug after your transplant, and you do not have any signs that your original cancer has come back.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
This trial tests a new drug (axatilimab) combined with a light-based blood treatment (ECP) for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It's for those who have already tried at least 2 other treatments or need high doses of steroids.
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
This study tests a new drug called axatilimab for children and teens with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The goal is to see if axatilimab works better than the usual care options. Participants will be randomly assigned to receive either axatilimab or one of several standard treatments.
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.